News from ptc therapeutics, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 22, 2012, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Receives $1 Million Grant Award from the National Institutes of Health (NIH) to Support Research for a Treatment for Dengue Fever

 PTC Therapeutics, Inc. (PTC) today announced the receipt of a $1 million grant award from the National Institute of Allergy and Infectious...

Sep 28, 2012, 08:00 ET
Dr. Jerome Zeldis.  (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors

 PTC Therapeutics, Inc. (PTC) today announced the appointment of Jerome B. Zeldis, M.D., Ph.D., to the company's Board of Directors. Dr....

Jul 23, 2012, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Closes $30 Million Financing

 PTC Therapeutics, Inc. (PTC) today announced the completion of a $30 million financing. The round included a number of long-term investors...

Jul 11, 2012, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration

PTC Therapeutics, Inc. (PTC) today announced that it has selected an experimental drug candidate to advance in its BMI1 program for aggressive and...

Jun 27, 2012, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Initiates Open-Label Study for Ataluren in Patients with Nonsense Mutation Duchenne/Becker Muscular Dystrophy

PTC Therapeutics, Inc. (PTC) today announced the initiation of an open-label study in the European Union, Israel, Australia and Canada for...

Jun 08, 2012, 12:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results

 PTC Therapeutics, Inc. today announced the results from a Phase 3 study of ataluren, an investigational new drug, in patients with nonsense...

Apr 02, 2012, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Announces Executive Promotions

 PTC Therapeutics, Inc. (PTC) today announced the promotions of Claudia Hirawat to President and Mark Boulding to Executive Vice President and...

Dec 22, 2011, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics' Antibacterial Program Receives $5 Million Award from the Wellcome Trust

 PTC Therapeutics, Inc. (PTC) today announced the receipt of a $5 million Seeding Drug Discovery (SDD) Award from the Wellcome Trust to...

Nov 29, 2011, 08:00 ET

Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)

 Roche (SIX: RO, ROG; OTCQX: RHHBY), PTC Therapeutics, Inc. (PTC) and the SMA Foundation, announced today a licensing agreement for PTC's...

Nov 07, 2011, 12:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Receives Grand Challenges Explorations Funding

PTC Therapeutics, Inc. announced today that it will receive funding through Grand Challenges Explorations, an initiative created by the Bill &...

Sep 02, 2011, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics and Genzyme Announce Restructuring of Collaboration

 PTC Therapeutics, Inc. and Genzyme, a Sanofi company, announced today the restructuring of their collaboration. Under the original...

Jul 01, 2011, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal

PTC Therapeutics, Inc. (PTC) today announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with...

Mar 30, 2011, 08:00 ET

PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer

PTC Therapeutics, Inc. (PTC) today announced the appointment of Robert J. Spiegel M.D., FACP as Chief Medical Officer.  Dr. Spiegel served...

Mar 02, 2011, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Announces Achievement of Milestone in BMI1 Collaboration With the Wellcome Trust

PTC Therapeutics, Inc. (PTC) today announced that it has identified a chemical series of molecules that penetrates the blood-brain barrier in...

Feb 01, 2011, 13:00 ET

PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients

PTC Therapeutics, Inc. (PTC) and Parent Project Muscular Dystrophy (PPMD) today announced an expansion of their collaboration to discover new...

Jan 19, 2011, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics' President and CEO Elected AAAS Fellow

Stuart W. Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc. (PTC), has been elected a Fellow of the American Association for the...

Dec 21, 2010, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis

PTC Therapeutics, Inc. announced today that it has completed enrollment of a Phase 3 clinical trial of ataluren, an investigational new drug, in...

Dec 01, 2010, 08:00 ET

Observational Data From One-Year Follow-up Study Validate Six-Minute Walk Distance as an Outcome Measure in Duchenne and Becker Muscular Dystrophy

Data published in the December issue of the medical journal Muscle and Nerve confirm the utility of six-minute walk distance (6MWD) as a...

Nov 15, 2010, 08:00 ET

PTC Publishes Results from Phase 2 Study of Ataluren in Children with Cystic Fibrosis

PTC Therapeutics, Inc. today announced the publication of data from a Phase 2a clinical trial of ataluren in children with nonsense mutation cystic...

Oct 26, 2010, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Initiates Phase 2 Clinical Trial of Ataluren in Patients With Methylmalonic Acidemia

PTC Therapeutics, Inc. today announced that it is expanding the development of ataluren, an investigational new drug, with the initiation of a...